Results 171 to 180 of about 191,459 (192)

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

The Lancet Gastroenterology and Hepatology, 2022
exaly  

Open-Label Placebo in Children With Abdominal Pain or IBS

AAP Grand Rounds, 2022
openaire   +1 more source

Placebo effects and their determinants in gastrointestinal disorders

Nature Reviews Gastroenterology and Hepatology, 2015
Sigrid Elsenbruch, Paul Enck
exaly  

Biological, clinical, and ethical advances of placebo effects

Lancet, The, 2010
Fabrizio Benedetti
exaly  

Open-Label-Placebo bei PMS-Beschwerden

gynäkologie + geburtshilfe
openaire   +1 more source

Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2004
Gilles Cambonie
exaly  

Open-label nondeceptive placebos

openaire   +1 more source

Open-Label Placebos to Treat Fatigue in Multiple Sclerosis

Case Medical Research, 2019
openaire   +1 more source

Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial

Psychotherapy and Psychosomatics, 2016
Michael, Schaefer, Rebecca, Harke, Claudia, Denke   +2 more
openaire   +2 more sources

Open Letter to Dr. L. Wittelshoefer

Ca-A Cancer Journal for Clinicians, 1972
exaly